Tikvah Therapeutics, a startup focused central nervous system disorders, has closed on $10 million in financing, VentureWire reported on Wednesday.
Tikvah launched in April of 2006.
The company’s focus is on finding new uses for drugs that have already been approved for use. The strategy is designed to shorten approval time and also lessen commercial risk of failure.
Its primary focus is on psychiatry and neurology.
In Feburary, Tikvah signed a license agreement with Therapade Technologies for worldwide development of a treatment of several anxiety-related disorders. Therapade was launched by researchers at Emory University and the College of William and Mary.
